Long-COVID – What Are the Long-term Effects of COVID-19?

Link: https://www.genre.com/knowledge/publications/rpakt20-2-dorn-en.html

Excerpt:

The COVID Symptom Study App provides a first overview of who is more likely to develop Long-COVID after an acute infection. More than four million users have described their post-COVID symptoms here.

The first published evaluation of slightly more than 4,000 participants showed that one in 22 COVID‑19 cases is still affected by Long-COVID symptoms eight weeks later; every 44th person maintains symptoms after four more weeks.66

Risk factors identified here are an increased BMI and higher age, although any age group can be affected. In the younger age group, the risk for women seems to be higher than for men. Since males have a higher risk of a severe acute COVID‑19 disease, this raises further questions about the underlying differences. For Long-COVID, there may be a connection with the fact that chronic fatigue syndrome occurs more often in women than in men.67 Asthma is another risk factor for Long-COVID. In general, the probability for Long-COVID increased with the number of symptoms in the first week.

Author(s): Dr. Katharina Dorn, Life/Health Associate Underwriter, Cologne

Publication Date: February 2021

Publication Site: Gen Re

A New Disease – Underwriting Without Evidence

Link: https://www.genre.com/knowledge/publications/uwfocus20-2-tiedemann-en.html

Excerpt:

As mentioned above, the selection of appropriate evidence is one of the most important steps in the derivation of evidence-based risk assessment guidelines. With little evidence available, this choice becomes easy, but the output may not always be satisfactory.

In the case of COVID‑19, it is not the lack of evidence as such, but the lack of long-term evidence that is a challenge. In contrast to this, the quantity of available short-term evidence is and has been record‑breaking.

This included numerous clinical studies. Since the beginning of the pandemic, new ones have been published seemingly almost every minute. While the quality of the studies may be good, they often look at small case counts only. In many instances, they were published in a preliminary stage to speed up the process of understanding the new disease. While this is reasonable to drive the scientific process, the level of certainty needed for decisions requires long-term evidence.

Author(s): Annika Tiedemann, Life/Health Underwriting Manager, Cologne

Publication Date: March 2021

Publication Site: Gen Re

Underwriting in China – A Digital Transformation

Link: https://www.genre.com/knowledge/publications/ri21-2-en.html

Excerpt:

The Life insurance market in China has grown tremendously with premiums increasing nearly three-fold from RMB1.06 trillion in 2010 to RMB2.96 trillion in 2019. With a population now close to 1.4 billion, the insurance penetration – which has grown to 4.6% – is still far from that of developed countries. Together this represents a business development opportunity because we expect the trend of growth in the insurance market to continue.

In anticipation, insurers in China began to move their underwriting from a paper process to an online one approximately three years ago. Today the bulk of transactions are paperless, except for a small volume of bank channel applications. However, given the huge daily volume of new business, insurers still have an urgent need to improve their processes further. While we are not suggesting a major overhaul of underwriting is needed, there is room to incorporate innovative ideas that address various pain points, provide a smoother customer experience while still balancing risk management needs.

Author(s): Orchis Li, Life/Health General Manager, Hong Kong; Dr. Celia Zhang Ying, Life/Health Regional Chief Underwriter & Senior Medical Officer, Shanghai

Publication Date: February 2021

Publication Site: Gen Re